Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical program goals for 2020 at the Biotech Showcase 2020 Conference in San Francisco, CA.
|
Biotech Showcase 2020 Conference Presentation Details: |
|
|
Date: |
Tuesday, January 14, 2020 |
|
Time: |
10:30am (PST) |
|
Track: |
Yosemite A (Ballroom Level) |
|
Venue: |
Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA |
Archived versions of the presentations will be made available through the Inovio Investor Relations Events page.
Inovio anticipates for 2020 to be a transformative year for the company. At the Biotech Showcase 2020 presentation, Dr. Kim will highlight multiple value-driving catalysts, clinical development, and program readouts which are all expected this year.
VGX-3100/INO-3107: HPV-Related Diseases
- VGX-3100. Inovio expects to report VGX-3100 REVEAL 1 top-line efficacy data in the fourth quarter of 2020. Through extensive work on amending the clinical readout timing a year earlier than originally designed, these early top-line data will be made available without compromising the integrity of both REVEAL 1 and REVEAL 2 trials. If positive, Phase 3 top-line data could provide further regulatory validation for this first-in-class DNA Medicine for treating cervical dysplasia.
- INO-3107. Inovio continues to expand its DNA Medicine franchise to treat HPV-related diseases by advancing INO-3107 to treat RRP, an orphan disease indication with a potential accelerated regulatory pathway.
- In the first half of this year, Inovio plans to initiate a Phase 2 clinical trial of INO-3107 for RRP, which impacts both pediatric and adult patients. RRP is caused by HPV 6 and 11 infections, which form non-cancerous tumors in the airways of patients who suffer from this disease. Currently, the disease is incurable and can only be treated by frequent surgeries to remove the tumors, which temporarily restores the airway before renewed tumor growth.
- In a previous pilot study, two adult patients with RRP had required surgery approximately every six months to clear tumor growth from their throats. Since their last dose of Inovio's HPV product candidate, both patients have been able to avoid or significantly delay surgery. One patient has not needed surgery for almost three years as of the last follow-up. The other patient did not require surgical intervention for approximately one and a half years, a significant delay in surgery intervals prior to the trial enrollment.
- Inovio believes INO-3107 could provide a novel treatment option for patients and a significant commercial opportunity for Inovio. Inovio is fully committed to bringing this product candidate to the market as soon as possible using all of the regulatory and development pathways available for rare, orphan diseases.
Dr. J. Joseph Kim, Inovio's President & CEO said, "In July, Inovio management took the difficult but necessary step to streamline expenses and prioritize our pipeline candidates. We have also accelerated important REVEAL 1 top-line data readout to the fourth quarter of 2020, allowing the market and potential global partners to see this data sooner than expected and moved to rapidly advance INO-3107, an orphan eligible and fast-to-market product candidate.
"Looking ahead, the coming year sets up to be a transformational period for Inovio, with top-line efficacy data from our REVEAL 1 Phase 3 trial, in addi...
(All Rights Reserved)